Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

Abstract Antibody–drug conjugates (ADCs) represent a novel class of biopharmaceuticals comprising monoclonal antibodies covalently conjugated to cytotoxic agents via engineered chemical linkers. This combination enables targeted delivery of cytotoxic agents to tumor site through recognizing target a...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruili Wang, Baohui Hu, Ziyu Pan, Chongxia Mo, Xin Zhao, Guojia Liu, Ping Hou, Qi Cui, Zhao Xu, Wenjia Wang, Zhaojin Yu, Lin Zhao, Miao He, Yan Wang, Chen Fu, Minjie Wei, Lifeng Yu
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Journal of Hematology & Oncology
Subjects:
Antibody–drug conjugates
Monoclonal antibody
Cytotoxic agents
Linkers
Targeted therapy
Clinical application
Online Access:https://doi.org/10.1186/s13045-025-01704-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13045-025-01704-3

Similar Items